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Chronic kidney disease (CKD) is associated with a high risk
for cardiovascular and all-cause mortality and premature
aging [1, 2]. Already in 2002, Himmelfarb et al. suggested
that oxidative stress is a “unifying concept of cardiovascular
disease in uremia” [3]. For several years now, researchers and
clinicians in nephrology have been working on the proof and
extension of this concept, on refining and arguing its details,
and on the desired implementation of respective therapies
and biomarkers. The present special issue aims to inform
the readership on latest developments on various aspects
of oxidative stress research in CKD and to foster further
research in the field.
E. Dounousi et al. contributed an interesting study to
strengthen the hypothesis that oxidative stress is involved
in the pathogenesis of cardiomyopathy in CKD. They inves-
tigated the association between the Paraoxonase-1 Q192R
gene variant and cardiomyopathy. Paraoxonase-1 (PON1)
belongs to the Paraoxonase family and exerts a protective
effect against lipoprotein oxidation. PON1 is diminished in
patients with CKD and has been suggested as a marker for
antioxidant status [4]. In their article now E. Dounousi et al.
show that the R allele of the Q192R variant in the PON1 gene
is dose-dependently related to the severity of left ventricular
hypertrophy and left ventricular dysfunction in CKD. They
also proved that the group of patients that was homozygous
for the R allele showed significantly higher concentrations of
the lipid peroxidation marker 8-isoprostane in plasma. The
authors discuss that the patients enrolled in this studywere all
Caucasians recruited from a restricted geographical area and
point out that confirmatory studies in CKD patient cohorts
with different geographical and ethnic background are
desirable.
K. Poulianiti et al. present a systematic review about sys-
temic redox imbalances in CKD.They focus on the impact of
disease severity, anemia therapy, mode of dialysis treatment,
and antioxidant interventions in both hemodialysis and peri-
toneal dialysis patients. Obviously, the imbalance in systemic
redox status is evident already at an early stage of CKD and
becomes more profound with kidney disease progression.
Evidence in early CKD is however limited and needs to
be expanded. Also, the authors conclude that hemodialysis
therapy per se seems to exert a negative influence on systemic
redox status but that other dialysismodalities have not proven
so far advantages with respect to the occurrence of oxidative
stress.The authors suggest that supplementationwith antioxi-
dantsmight be considered as an early intervention to halt pre-
mature cardiovascular disease in CKD. Intervention studies,
however, especially also in this patient group with early CKD
are hampered by small sample size and relatively short
duration.
J. Yu et al. explored the role of cell-targeted antioxidant
interventions and more specifically investigated the effects
of the cell-permeable superoxide dismutase (SOD) mimetic
Mn(III)tetrakis (4-benzoic acid) porphyrin (MnTBAP) on
renal oxidative stress and fibrosis in a mouse model of
CKD. They found that fibrotic transition and mitochondrial
dysfunction after transforming growth factor-𝛽1 treatment
of mouse tubular epithelial cells could be reduced by pre-
treatment with MnTBAP. Furthermore, in uremic mice,
intraperitoneal injection of MnTBAP resulted in a reduction
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of renal fibrosis in the remnant kidney. The authors suggest
that MnTBAP therapy might serve as a promising strategy
to prevent renal fibrosis in CKD via antagonistic effects
on mitochondrial-derived oxidative stress and subsequent
protection of mitochondrial function. These findings appear
promising and necessitate further investigation especially in
the light of the recently discussed prooxidative activities of
metal porphyrins used as SODmimetics in biological systems
[5].
The reasons that underlie the wish for the application
of antioxidant therapy in CKD are numerous including a
reduction of CKD-related increased cancer incidence. One
strategy to reduce cancer risk is interventions to reduce
genomic damage which is also increased in CKD patients.
Such approaches necessitate a reliable analysis of DNA. Here,
the article by N. Schupp et al. in this issue will be read
by nephrological researchers and clinicians likewise with
great interest. The authors provide an in depth review of
biomarkers forDNAdamage inCKD.They explain, compare,
and evaluate the most common methods that are currently
used to quantify DNA damage in CKD patients, discuss the
markers’ potential to predict clinical outcomes, and provide
information about ongoing efforts for standardization.
The review by J. Pedraza-Chaverri et al. discusses some
newer aspects of pathogenesis of oxidative stress and antiox-
idant therapy in CKD.The authors provide an overview over
selected current antioxidant interventions and discuss new,
not yet fully elucidated concepts of oxidative stress genesis. So
the impact of mitochondrial alterations in CKD and possible
connections to the development of cardiovascular disease
are highlighted. Also, the authors provide information on
two controversial players for the redox balance in CKD:
hyperuricemia and vitamin D deficiency. Underlying molec-
ular mechanisms and pharmacological interventions are pre-
sented. Finally, emerging therapies for diabetic nephropathy,
including sodium-glucose cotransporter 2 inhibitors and
alternative, traditional medicines, are discussed.
In summary, this special issue demonstrates that knowl-
edge on causes and consequences of oxidative stress in CKD
is rapidly expanding. Many gaps, however, remain, calling
for additional research efforts to unravel its pathogenesis
and to test therapeutic approaches. No simple antioxidant
solutions are at hand and solid clinical outcome data both
for biomarker research and for interventions studies are
necessary. Moreover, when analyzing oxidative stress related
molecular changes and the impact of antioxidant inter-
ventions, important variables such as CKD stage, genetic
background, current therapies, and comorbidities should be
accounted for.
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